z-logo
open-access-imgOpen Access
LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple‐negative breast cancer
Author(s) -
Wang Wei,
He Xionghui,
Wang Yiqing,
Liu Haiying,
Zhang Fan,
Wu Zhong,
Mo Shaowei,
Chen Dong
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15370
Subject(s) - triple negative breast cancer , gene knockdown , anaerobic glycolysis , cancer research , breast cancer , lactate dehydrogenase , biology , cell growth , cancer , cell , cell migration , lactate dehydrogenase a , glycolysis , malignancy , cell culture , cancer cell , medicine , endocrinology , enzyme , metabolism , biochemistry , genetics
Abstract Breast cancer is the most prevalent cancer diagnosed in women and the major malignancy that threatens women health, thus we explored the role of long noncoding RNA LINC01605 in triple‐negative breast cancer (TNBC). We collected tissue samples from TNBC patients and cultured breast cancer cells to detect LINC01605 levels by RT‐PCR. We then constructed LINC01605 knockdown and LINC01605 overexpressed TNBC cell lines, cell proliferation was measured by CCK‐8 and colony formation assays, cell migration and invasion were measured by Transwell assay, and aerobic glycolysis of cells was detected. Furthermore, a downstream target gene was found, and its role was confirmed by mouse allogeneic tumor formation. It discovered that LINC01605 expression was significantly increased in TNBC patients, and its high expression predicted a low survival prognosis for TNBC patients. Stable knockdown of LINC01605 remarkably inhibited cell proliferation, migration, and invasion, as well as aerobic glycolysis by inhibiting lactate dehydrogenase A in TNBC cell lines. Notably, knockdown of LINC01605 suppressed in vivo tumor formation and migration in TNBC transplanted mice. In conclusion, targeting long noncoding RNA LINC01605 might serve as a therapeutic candidate strategy to treat patients with TNBC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here